文献速递妇科

双示踪剂两步法前哨淋巴结活检在早期子宫内膜癌中的应用

[Application of the two-step sentinel lymph node biopsy with double-tracer in early staged endometrial cancer].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2022-01-01

该研究纳入73例早期子宫内膜癌患者,随机分为宫颈注射组、宫体注射组和联合注射组,评估双示踪两步法前哨淋巴结活检的可行性。结果显示联合注射可提高腹主动脉旁前哨淋巴结检出率,前哨淋巴结活检对低危患者敏感度和阴性预测值均为100%,作者认为可作为低危患者系统性淋巴结切除术的替代方案。

要点

  • 前哨淋巴结活检对早期子宫内膜癌总敏感度89%、阴性预测值98%。
  • 联合注射组腹主动脉旁前哨淋巴结检出率67%显著高于宫颈注射组28%。
  • 低危患者前哨淋巴结活检敏感度和阴性预测值均为100%。

核心结论

  • 前哨淋巴结活检对早期子宫内膜癌患者具有较高的敏感度和阴性预测值,可作为低危型患者系统性淋巴结切除术的替代方案。
  • 两步法双示踪可进一步提高前哨淋巴结检出率,尤其可有效避免腹主动脉旁阳性前哨淋巴结的漏检,作者推荐用于中高危型或肿瘤累及宫底部的患者。

研究设计与样本

  • 研究为随机对照研究,纳入2019年7月至2021年4月在青岛大学附属医院术前诊断为Ⅰ~Ⅱ期子宫内膜癌行手术治疗的患者73例,年龄(54.2±3.3)岁,其中低危型56例、中高危型17例。
  • 按示踪剂注射部位随机分为宫颈注射组25例(纳米炭1 ml于子宫颈3点和9点注射)、宫体注射组21例(亚甲蓝4 ml于病灶所在子宫体部位分2点注射)和联合注射组27例(子宫颈注射纳米炭1 ml联合子宫体注射亚甲蓝4 ml)。
  • 所有患者均在腹腔镜下完成分期手术,前哨淋巴结切除后行冰冻病理检查,术后病理阴性者进一步行病理超分期检查。

主要发现

  • 73例患者前哨淋巴结总检出率88%(64/73),双侧盆腔前哨淋巴结检出率67%(49/73),腹主动脉旁前哨淋巴结检出率49%(36/73)。
  • 宫体注射组前哨淋巴结总检出率71%(15/21)显著低于宫颈注射组92%(23/25)和联合注射组96%(26/27),双侧盆腔检出率43%(9/21)显著低于宫颈注射组76%(19/25)和联合注射组78%(21/27),P均<0.05。
  • 宫颈注射组腹主动脉旁前哨淋巴结检出率28%(7/25)显著低于宫体注射组52%(11/21)和联合注射组67%(18/27),P均<0.05。
  • 73例中术后病理证实淋巴结转移9例,前哨淋巴结检出8例,总敏感度89%、阴性预测值98%;宫颈注射组和联合注射组敏感度和阴性预测值均为100%,宫体注射组敏感度67%、阴性预测值95%。
  • 56例低危型患者中1例前哨淋巴结阳性且术后病理证实淋巴结转移,转移率2%(1/56),敏感度和阴性预测值均为100%;17例中高危型患者中8例(8/17)术后证实淋巴结转移,敏感度88%、阴性预测值90%。

关键数值与推荐

  • 前哨淋巴结活检诊断淋巴结转移的总敏感度89%、阴性预测值98%。
  • 低危型患者前哨淋巴结活检敏感度和阴性预测值均为100%,转移率2%(1/56)。
  • 中高危型患者前哨淋巴结活检敏感度88%、阴性预测值90%。
  • 联合注射组腹主动脉旁前哨淋巴结检出率67%(18/27)显著高于宫颈注射组28%(7/25),P<0.05。
  • 前哨淋巴结低体积转移率8%(5/64)。

临床怎么用

  • 作者认为前哨淋巴结活检可作为低危型早期子宫内膜癌患者系统性淋巴结切除术的替代方案。
  • 作者推荐中高危型或肿瘤累及宫底部的患者使用宫颈-宫体联合注射的两步法双示踪进行前哨淋巴结示踪。
  • 宫颈注射组和联合注射组前哨淋巴结诊断淋巴结转移的敏感度和阴性预测值均为100%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the feasibility and clinical value of sentinel lymph node (SLN) biopsy through cervix-uterine combined two-step injection with two tracers in patients with early stage endometrial cancer. Methods: From July 2019 to April 2021, a total of 73 patients, aged (54.2±3.3) year, who were preoperatively diagnosed as stage Ⅰ-Ⅱ endometrial cancer (including 56 low-risk patients and 17 medium-high risk patients) in Affiliated Hospital of Qingdao University were selected. According to the different sites of tracer injection, the patients were randomly divided into three groups: cervical injection group (25 cases): 1 ml of nano-carbon was used to inject at 3 and 9 o'clock in the cervix; uterine injection group (21 cases): the magnetic resonance imaging examination was performed to determine the location of the lesion, and 4 ml of methylene blue was injected into the uterine body at 2 sites where the lesion was located; combined injection group (27 cases): cervical injection of nano-carbon (1 ml) combined with uterine injection of methylene blue (4 ml). The SLN in all patients were identified under laparoscopy, removed, and followed by frozen pathological examination. Pathological ultra-staging was performed if the postoperative pathological outcome of SLN was negative. The total detection rate of SLN, bilateral pelvic SLN detection rate, sensitivity, negative predictive value, and location of SLN in each group were calculated and compared. Results: (1) In 73 patients with endometrial cancer, the overall detection rate of SLN was 88% (64/73), the detection rate of bilateral pelvic SLN was 67% (49/73), and the detection rate of para-aortic SLN was 49% (36/73). The overall detection rate of SLN (71%, 15/21) and bilateral pelvic SLN (43%, 9/21) in the intrauterine injection group were significantly lower than those in the cervical injection group [92% (23/25), 76% (19/25), respectively] and the combined injection group [96% (26/27), 78% (21/27), respectively; all P<0.05]; the detection rate of para-aortic SLN in the cervical injection group (28%, 7/25) was significantly lower than those in the intrauterine injection group and combined injection group [52% (11/21) and 67% (18/27), respectively; both P<0.05]. Among 73 cases with endometrial cancer, 9 had lymph node metastasis confirmed by postoperative pathological examination, 8 of them had lymph node metastasis detected by SLN and 1 had no lymph node metastasis detected by SLN, with a total sensitivity of 89% and a negative predictive value of 98%. The sensitivity and negative predictive value of cervical injection group and combined injection group were 100%, while the sensitivity and negative predictive value of intrauterine injection group were 67% and 95%. Among 56 low-risk patients, only one patient with lymph node metastasis was confirmed by postoperative pathology by SLN detection, and the metastasis rate was 2% (1/56), and the sensitivity and negative predictive value were 100%. Lymph node metastasis was confirmed in 8 of 17 patients (8/17) with a sensitivity of 88% and a negative predictive value of 90%. (2) A total of 459 SLN were detected in 73 endometrial cancer patients, with the highest proportion of external iliac (33.3%, 153/459).The obturator foramen was 25.3% (116/459), para-aortic 19.6% (90/459), iliac 12.0% (55/459), and presacral 9.8% (45/459). The proportion of para-aortic SLN in the cervical injection group was 12.4% (21/169), which were significantly lower than that in the intrauterine injection group and the combined injection group [27.4% (26/95) and 22.1% (43/195), respectively; both P<0.05]. (3) Pathological super-staging results: among 64 patients with negative SLN routine paraffin pathology, 4 cases of lymph node micro-metastases and 1 case of isolated tumor cell metastasis were detected, and the SLN micro-metastases rate was 8% (5/64), including 2 cases of low-risk patients and 3 cases of medium-high risk patients. Conclusions: SLN biopsy has high sensitivity and negative predictive value in patients with early endometrial cancer and could be used as an alternative to systematic lymph node dissection in low-risk patients. The SLN mapping through cervical-uterine combined injection could further improve the detection rate effectively and avoid the missed detection of positive para-aortic lymph node, especially for high-risk patients or patients with fundal tumor involvement. 目的: 探讨在早期子宫内膜癌患者中应用两种示踪剂通过子宫颈、子宫体联合注射(即两步法双示踪)进行前哨淋巴结(SLN)活检的可行性及临床价值。 方法: 选择2019年7月至2021年4月在青岛大学附属医院因术前诊断为早期(Ⅰ~Ⅱ期)子宫内膜癌行手术治疗的患者共73例,其年龄为(54.2±3.3)岁;其中低危型56例,中高危型17例。按示踪剂注射部位不同随机(直接抽样法)分为3组:宫颈注射组(25例):纳米炭1 ml于子宫颈3点和9点注射;宫体注射组(21例):盆腔磁共振成像(MRI)检查确定病灶部位,亚甲蓝4 ml于病灶所在的子宫体部位分2点注射;联合注射组(27例):子宫颈注射纳米炭(1 ml)联合子宫体注射亚甲蓝(4 ml)。所有患者均在腹腔镜下完成子宫内膜癌分期手术,若术后病理检查SLN为阴性则进一步行病理超分期检查。比较3组子宫内膜癌患者的SLN检出率、SLN分布部位及SLN病理超分期检查结果,并计算3组SLN诊断淋巴结转移的敏感度、阴性预测值。 结果: (1)SLN检出率:73例子宫内膜癌患者中,SLN总检出率为88%(64/73),双侧盆腔SLN检出率为67%(49/73),腹主动脉旁SLN检出率为49%(36/73)。宫体注射组的SLN总检出率(71%,15/21)、双侧盆腔SLN检出率(43%,9/21)均显著低于宫颈注射组[分别为92%(23/25)、76%(19/25)]、联合注射组[分别为96%(26/27)、78%(21/27);P均<0.05];宫颈注射组的腹主动脉旁SLN检出率(28%,7/25)显著低于宫体注射组、联合注射组[分别为52%(11/21)、67%(18/27);P均<0.05]。73例子宫内膜癌患者中,术后病理检查证实淋巴结转移者9例,其中8例SLN阳性、1例SLN未检测出淋巴结转移,SLN检测诊断子宫内膜癌患者淋巴结转移的总敏感度为89%、阴性预测值为98%;其中宫颈注射组和联合注射组的敏感度和阴性预测值均为100%,宫体注射组的敏感度为67%,阴性预测值95%。56例低危型患者中,仅1例SLN阳性患者术后病理证实淋巴结转移,转移率为2%(1/56),SLN检测诊断低危型患者淋巴结转移的敏感度和阴性预测值均为100%。17例中高危型患者中,8例(8/17)术后证实淋巴结转移,包括7例SLN阳性和1例SLN阴性患者,SLN检测诊断中高危型患者淋巴结转移的敏感度为88%、阴性预测值90%。(2)SLN分布部位:73例子宫内膜癌患者共检出SLN 459枚,显影比例最高的部位为髂外33.3%(153/459),其次为闭孔25.3%(116/459)、腹主动脉旁19.6%(90/459)、髂总12.0%(55/459)和骶前9.8%(45/459)。宫颈注射组腹主动脉旁SLN占12.4%(21/169),显著低于宫体注射组和联合注射组[分别为27.4%(26/95)、22.1%(43/195);P均<0.05]。(3)病理超分期检查结果:64例SLN常规石蜡病理为阴性的患者中,检出4例淋巴结微小转移和1例孤立肿瘤细胞转移,SLN低体积转移(包括微小转移和孤立肿瘤细胞转移)率为8%(5/64),其中低危型患者2例,中高危型患者3例。 结论: SLN示踪对早期子宫内膜癌患者具有较高的敏感度和阴性预测值,可作为低危型患者系统性淋巴结切除术的替代方案。两步法双示踪可以进一步提高SLN的检出率,尤其可以有效避免腹主动脉旁阳性SLN的漏检,对于中高危型或肿瘤累及宫底部的患者推荐使用。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang YN, Xia YF, Chen YQ, et al. [Application of the two-step sentinel lymph node biopsy with double-tracer in early staged endometrial cancer]. Zhonghua Fu Chan Ke Za Zhi. 2022. PMID: 36456477. doi:10.3760/cma.j.cn112141-20220323-00185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。